| 000 | 01539 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250514015335.0 | ||
| 264 | 0 | _c20020327 | |
| 008 | 200203s 0 0 eng d | ||
| 022 | _a1352-0504 | ||
| 024 | 7 |
_a10.1046/j.1365-2893.2001.00320.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLin, C C | |
| 245 | 0 | 0 |
_aLong-term evaluation of recombinant interferon alpha2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan. _h[electronic resource] |
| 260 |
_bJournal of viral hepatitis _cNov 2001 |
||
| 300 |
_a438-46 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 | _aCase-Control Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aHepatitis B e Antigens _xblood |
| 650 | 0 | 4 |
_aHepatitis B, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aTaiwan |
| 700 | 1 | _aWu, J C | |
| 700 | 1 | _aChang, T T | |
| 700 | 1 | _aHuang, Y H | |
| 700 | 1 | _aWang, Y J | |
| 700 | 1 | _aTsay, S H | |
| 700 | 1 | _aChow, N H | |
| 700 | 1 | _aChang, F Y | |
| 700 | 1 | _aLee, S D | |
| 773 | 0 |
_tJournal of viral hepatitis _gvol. 8 _gno. 6 _gp. 438-46 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1046/j.1365-2893.2001.00320.x _zAvailable from publisher's website |
| 999 |
_c11618794 _d11618794 |
||